Produktbild: Patient Surveillance After Cancer Treatment

Patient Surveillance After Cancer Treatment

Fr. 265.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.04.2015

Herausgeber

Frank E. Johnson + weitere

Verlag

Humana Press

Seitenzahl

538

Maße (L/B/H)

27.9/21/3 cm

Gewicht

1364 g

Auflage

2013

Sprache

Englisch

ISBN

978-1-62703-965-9

Beschreibung

Rezension

From the reviews:

“This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. … Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. … This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent.” (Judith G. Abramson, Doody’s Book Reviews, September, 2013)

“Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. … This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library.” (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.04.2015

Herausgeber

Verlag

Humana Press

Seitenzahl

538

Maße (L/B/H)

27.9/21/3 cm

Gewicht

1364 g

Auflage

2013

Sprache

Englisch

ISBN

978-1-62703-965-9

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Patient Surveillance After Cancer Treatment
  • 1. Overview

    David Y. Johnson and Frank E. Johnson

     

    2. Introduction to Cancer Surveillance Strategies

    Brooke Crawford and David D. Greenberg

     

    3. Using Decision Analysis to Model Cancer Surveillance

    Kim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg

     

    4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment

    Craig C. Earle and Jennifer Deevy

     

    5. Upper Aerodigestive Tract Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe

    Béatrix Barry and Dominique De Raucourt

     

    7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan

    Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune

     

    8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada

    Richard W. Nason and James B. Butler

     

    9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia

    Leigh Delbridge

     

    11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan

    Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune

     

    12. Lung Carcinoma

    Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

     

    13. Lung Carcinoma Surveillance Counterpoint: Australia

    Michael Boyer and Kate Mahon

     

    14. Lung Carcinoma Surveillance Counterpoint: Japan

    Tokujiro Yano and Yoshihiko Maehara

     

    15. Lung Carcinoma Surveillance Counterpoint: Canada

    Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans

     

    16. Esophagus Carcinoma

    Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

     

    17. Esophagus Carcinoma Surveillance Counterpoint: Australia

    Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister

     

    18. Esophagus Carcinoma Surveillance Counterpoint: Japan

    Masaru Morita and Yoshihiko Maehara

     

    19. Stomach

    Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

     

    20. Stomach Carcinoma Surveillance Counterpoint: USA

    Andrew Coleman and Douglas Tyler

     

    21. Stomach Carcinoma Surveillance Counterpoint: Japan

    Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara

     

    22. Pancreatic Adenocarcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA

    Tanios S. Bekaii-Saab

     

    24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe

    Richard A. Smith, Jane V. Butler, and John P. Neoptolemos

     

    25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan

    Ken Shirabe and Yoshihiko Maehara

     

    26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada

    Malcolm J. Moore and Anastasios Stathis

     

    27. Liver and Biliary Tract Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe

    Michele Colledan

     

    29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia

    Michael D. Crawford

     

    30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan

    Akinobu Taketomi and Yoshihiko Maehara

     

    31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada

    Oliver F. Bathe and Kelly Warren Burak

     

    32. Colon and Rectum Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA

    Mohamedtaki A. Tejani and Steven J. Cohen

     

    34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia

    Toufic El-Khoury, Michael Solomon, and Jane Young

     

    35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan

    Yasushi Toh and Yoshihisa Sakaguchi

     

    36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada

    Marko Simunovic

     

    37. Anal Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    38. Anal Carcinoma Surveillance Counterpoint: USA

    Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata

     

    39. Anal Carcinoma Surveillance Counterpoint: Australia

    Toufic El-Khoury, Michael Solomon, and Jane Young

     

    40. Anal Carcinoma Surveillance Counterpoint: Japan

    Yoshihisa Sakaguchi and Yasushi Toh

     

    41. Anal Carcinoma Surveillance Counterpoint: Canada

    Natasha Press and John Hay

     

    42. Soft Tissue Sarcoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    43. Soft Tissue Sarcoma Surveillance Counterpoint: USA

    Valeriy Sedov and Janice M. Mehnert

     

    44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan

    Shuichi Matsuda and Yukihide Iwamoto

     

    45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada

    Lloyd A. Mack and Vivien H.C. Bramwell

     

    46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan

    Shuichi Matsuda and Yukihide Iwamoto

     

    48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada

    Timothy R. Asmis, Joel Werier, and Shailendra Verma

     

    49. Cutaneous Melanoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    50. Cutaneous Melanoma Surveillance Counterpoint: USA

    Gerald Linette and Lynn A. Cornelius

     

    51. Cutaneous Melanoma Surveillance Counterpoint: Australia

    Michael A. Henderson

     

    52. Cutaneous Melanoma Surveillance Counterpoint: Japan

    Yoichi Moroi

     

    53. Breast Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    54. Breast Carcinoma Surveillance Counterpoint: USA

    Kelli Pettit and Julie A. Margenthaler

     

    55. Breast Carcinoma Surveillance Counterpoint: Europe

    Stefano Ciatto

     

    56. Breast Carcinoma Surveillance Counterpoint: Australia

    Andrew J. Spillane and Meagan E. Brennan

     

    57. Breast Carcinoma Surveillance Counterpoint: Japan

    Eriko Tokunaga and Yoshihiko Maehara

     

    58. Endometrial Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    59. Endometrial Cancer Surveillance Counterpoint: USA

    Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr.

     

    60. Endometrial Cancer Surveillance Counterpoint: USA

    Summer B. Dewdney and Premal H. Thaker

     

    61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan

    Yousuke Ueoka, Hiroaki Kobayashi, and Norio Wake

     

    62. Endometrial Carcinoma Surveillance Counterpoint: Canada

    Michael Fung-Kee-Fung and Thomas K. Oliver

     

    63. Cervical Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    64. Cervical Carcinoma Surveillance Counterpoint: USA

    Joshua P. Kesterson and Shashikant Lele

     

    65. Cervical Carcinoma Surveillance Counterpoint: Japan

    Kenzo Sonoda, Hiroaki Kobayashi, and Norio Wake

     

    66. Cervical Carcinoma Surveillance Counterpoint: Canada

    Michael Fung-Kee-Fung and Thomas K. Oliver

     

    67. Vaginal and Vulvar Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan

    Shinji Ogawa, Hiroaki Kobayashi, and Norio Wake

     

    69. Ovarian Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    70. Ovarian Carcinoma Surveillance Counterpoint: USA

    Maurie Markman

     

    71. Ovarian Cancer Surveillance Counterpoint: Europe

    Andy Nordin

     

    72. Ovarian Cancer Surveillance Counterpoint: Japan

    Hiroaki Kobayashi and Norio Wake

     

    73. Renal Carcinoma

    Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

     

    74. Renal Carcinoma Surveillance Counterpoint: Europe

    Alessandro Antonelli, Claudio Simeone, and Sergio Cosciani Cunico

     

    75. Renal Carcinoma Surveillance Counterpoint: Japan

    Masatoshi Eto, Wataru Takahashi, Yoshiaki Kawano, Jiro Honda, Juro Nakanishi, and Yoshihiro Wada

     

    76. Renal Carcinoma Surveillance Counterpoint: Canada

    Michael Leveridge, Robert Abouassaly, and Michael A.S. Jewett

     

    77. Urinary Bladder Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan

    Kentaro Kuroiwa

     

    79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada

    Faysal A. Yafi and Wassim Kassouf

     

    80. Prostate Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    81. Prostate Carcinoma Surveillance Counterpoint: USA

    Angela Smith and Raj Pruthi

     

    82. Prostate Carcinoma Surveillance Counterpoint: USA 

    Erik T. Goluboff and Matthew Wosnitzer

     

    83. Prostate Carcinoma Surveillance Counterpoint: Europe

    Stefano Ciatto

     

    84. Prostate Carcinoma Surveillance Counterpoint: Japan

    Akira Yokomizo

     

    85. Prostate Carcinoma Surveillance Counterpoint: Canada

    Andrew Loblaw and Colin Tang

     

    86. Testicle Carcinoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    87. Testicle Carcinoma Surveillance Counterpoint: USA

    Ian M. Thompson III and Sam S. Chang

     

    88. Testicle Carcinoma Surveillance Counterpoint: Australia

    Michael Boyer and Kate Mahon

     

    89. Testicle Carcinoma Surveillance Counterpoint: Japan

    Narihito Seki

     

    90. Lymphoma

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    91. Lymphoma Surveillance Counterpoint: USA

    Kenneth R. Carson and Nancy L. Bartlett

     

    92. Lymphoma Surveillance Counterpoint: Japan

    Kenjiro Kamezaki

     

    93. Lymphoma (Following Autologous Stem Cell Transplant)

    Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

     

    94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan

    Toshihiro Miyamoto

     

    95. Leukemia

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    96. Leukemia Surveillance Counterpoint: USA

    Olalekan Oluwole, Susan Greenhut, Bipin N. Savani, and Nishitha Reddy

     

    97. Leukemia Surveillance Counterpoint: Japan

    Koji Nagafuji

     

    98. Multiple Myeloma

    Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

     

    99. Multiple Myeloma Surveillance Counterpoint: USA

    Niyati Modi, G. David Roodman, and Suzanne Lentzsch

     

    100. Multiple Myeloma Surveillance Counterpoint: Australia

    Liane Khoo and Douglas Joshua

     

    101. Multiple Myeloma Surveillance Counterpoint: Japan

    Katsuto Takenaka

     

    102. Multiple Myeloma Surveillance Counterpoint: Canada

    Matthew C. Cheung and Kevin R. Imrie

     

    103. Glioma of the Central Nervous System

    David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

     

    104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe

    Wolfgang Grisold, Stefan Oberndorfer, and Eefje Sizoo

     

    105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia

    Margot Lehman and Michael Barton

     

    106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan

    Masahiro Mizoguchi, Koji Yoshimoto, and Tomio Sasaki